Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Accured Expenses (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Change in Accured Expenses data on record, last reported at $2.2 million in Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 605.88% year-over-year to $2.2 million; the TTM value through Dec 2025 reached $4.7 million, up 177.63%, while the annual FY2025 figure was $4.7 million, 177.63% up from the prior year.
  • Change in Accured Expenses reached $2.2 million in Q4 2025 per TRDA's latest filing, down from $3.7 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $6.9 million in Q3 2022 and bottomed at -$5.5 million in Q1 2025.
  • Average Change in Accured Expenses over 4 years is $751500.0, with a median of $1.8 million recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: crashed 795.59% in 2023, then skyrocketed 605.88% in 2025.
  • A 4-year view of Change in Accured Expenses shows it stood at -$4.3 million in 2022, then soared by 145.03% to $2.0 million in 2023, then crashed by 121.74% to -$425000.0 in 2024, then surged by 605.88% to $2.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $2.2 million in Q4 2025, $3.7 million in Q3 2025, and $4.3 million in Q2 2025.